By Colin Kellaher U.S.-listed shares of Kazia Therapeutics jumped in premarket trading Thursday after the Australian biotechnology company said...
By Colin Kellaher U.S.-listed shares of Kazia Therapeutics Ltd. jumped more than 15% in premarket trading Wednesday after the Australian...
Kazia and Kintara Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads